Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

This study is currently recruiting participants.

Verified May 2013 by Boehringer Ingelheim Pharmaceuticals

Sponsor:

Information provided by (Responsible Party):

Boehringer Ingelheim Pharmaceuticals

ClinicalTrials.gov Identifier:

NCT01721876

First received: November 2, 2012

Last updated: May 15, 2013

Last verified: May 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	April 2016
Estimated Primary Completion Date:	April 2016 (Final data collection date for primary outcome measure)